Tag Archives: Tendering and procurement

Shanxi Healthcare Security Bureau to Implement National TCM Alliance Fourth Batch and Second Batch Follow‑up VBP Results From Oct 15 – Province‑Wide Execution Through 2028 With Listing Suspensions and Price Risk Flags for Non‑Winning Products

Implementation Snapshot

Item	Detail
Authority	Shanxi Provincial Healthcare Security Bureau, China
Document	Jin Yi Bao Han [2026] No. 72 – Notice on implementing national TCM alliance winning results
Batches	National TCM Procurement Alliance Fourth Batch (ZCYLM‑2026‑1) and Second Batch follow‑up (ZCYLM‑2026‑2)
Institutional Scope	All provincial public medical institutions (incl. military), participating insurance‑designated private institutions and designated pharmacies
Execution Date	15 October 2026, province‑wide
Procurement Cycle	15 Oct 2026 – 31 Dec 2028; first year through 14 Oct 2027; agreements signed annually, renewal volumes in principle no less than prior year
Supply Rule	Winning enterprises supply at winning prices beyond agreed volumes until cycle expiry

Price Execution & Platform Measures

Listing & Tripartite Agreements: The provincial drug and device procurement center will list winning products at winning prices and organize tripartite contracts among winning manufacturers, distributors and medical institutions per volume‑based procurement (VBP) rules.
Listing Suspensions: Within the same procurement group (administration route), products already listed provincially but not declared in winning enterprises’ “supply lists” will be suspended from listing — except products containing both natural bezoar and natural musk.
Price Risk Flags: Non‑winning products, and natural bezoar/musk products outside winning supply lists, will carry price risk warning markers on the platform.

Usage, Assessment & Monitoring Requirements

Rational Use Mandate: Medical institutions must prioritize winning products and fulfill agreed volumes, while avoiding concentrated bulk purchasing of winners and any “one‑size‑fits‑all” cutoff of non‑winning products; where winning products force brand switches for patients, dedicated department and staff training plus patient explanation work is required.
Assessment Design: Winning‑product procurement and use enter institutional performance assessments; non‑winning products priced below the lowest winning price are excluded from execution assessment; drug volumes in special‑need and international medical services (outside basic insurance payment) are excluded from monitoring; same‑name/dosage/specification products of one winning enterprise with compliant price differentials across package sizes may be assessed on a merged basis — a rule extendable to other national TCM alliance batches.
Supply & Compliance Monitoring: Insurance departments will monitor winning‑enterprise supply and hospital execution, using reminders and accountability interviews for supply shortfalls, with escalation reporting for major quality or supply problems; institutions showing below‑schedule progress, markedly low winning‑product share, or “buying high, not low” will face notification, with further measures for inadequate rectification.
Policy Coordination: Procurement, supply assurance, payment settlement, insurance reimbursement and quality management responsibilities are assigned across relevant units to ensure the results take full effect.

Sector Background

National TCM Alliance: Led cross‑province centralized procurement of traditional Chinese patent medicines, extending VBP beyond chemical drugs into the TCM segment — one of China’s largest pharmaceutical categories by prescription volume.
Follow‑up (接续) Procurement: Successor rounds that re‑tender expiring batch agreements, stabilizing prices and supply continuity for previously procured products.
Supply‑List Mechanism: Winning enterprises declare distributable product lists that determine which comparable items remain listed — a lever to steer hospital purchasing toward winners without formally banning alternatives.

Market Impact & Outlook

Price Reset for TCM Makers: From 15 October, winning manufacturers gain contracted volume across Shanxi at alliance‑set prices, while non‑winners face platform flags or suspension — reshaping competitive positions per procurement group.
Volume Security for Winners: The “winning price applies beyond agreed volumes until cycle end” clause protects hospitals’ upside demand without further negotiation, and annual renewals anchored at no‑less‑than‑prior volumes give winners multi‑year visibility.
Compliance Watchpoints: Distributors and manufacturers should verify supply‑list inclusion, prepare tripartite contracts, and track the natural bezoar/musk exemption — the notable carve‑out reflecting scarcity‑driven pricing in premium TCM materials.
Replication Signal: The merged‑assessment approach and its extension to other alliance batches may preview softer, more practical execution metrics for TCM VBP nationwide.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of national TCM alliance procurement results in Shanxi, including price adjustments, listing actions and procurement volumes. Actual execution depends on platform operations, enterprise supply performance, institutional compliance and assessment outcomes, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://ybj.shanxi.gov.cn/xxfb/xxgkml/202609/t20260918_10222979.html

Guangdong Drug Exchange Center Publishes First September 2026 Batch of Newly Listed Bargaining‑Price Disinfection Products – Batch YJHCGW39‑20260901‑XD Joins Negotiated Procurement Scope for Hospitals Province‑Wide

Listing Snapshot

Item	Detail
Authority	Guangdong Drug Exchange Center (Guangdong Province, China)
Platform	Guangdong Third‑Party Drug Electronic Trading Platform – Medical Consumables Trading System
Action	Publication of newly listed bargaining‑price (议价挂网) disinfection products – first batch, September 2026
Batch	YJHCGW39‑20260901‑XD
Publication Date	17 September 2026
Product Scope	Disinfection products (消毒产品) declared by enterprises before 10 September 2026, price‑confirmed and listing‑applied via the automatic confirmation workflow; details in the attached product information table
Transaction Rule	Medical institutions procure by bargaining at prices not exceeding the listed price

Listing Process & Conditions

Automatic Confirmation Workflow: Covered products were declared through the system’s “Price Management – Consumables Bargaining‑Price Listing Addition (Automatic Confirmation Items)” module, where enterprises confirmed price information and submitted listing applications before the 10 September 2026 cut‑off.
Publicity‑Period Gate: Only products that received no objections during the publicity period are published in this batch; enterprises are directed to download the attached detailed product list themselves.
Deferred Listings: Products with information re‑verification pending or with registration certificates not yet fully effective will be listed only after verification concludes or product status becomes fully effective.
Policy Basis: The provincial platform’s announcement on implementing medical consumables listing procurement, the Center’s notice on optimizing routine drug and consumables listing work, and the notice activating the automatic viewing‑and‑confirmation process for bargaining‑price listed consumables price information.

Sector Background

Bargaining‑Price Listing (议价挂网): A procurement channel where the listed price serves as a ceiling and hospitals negotiate final prices with suppliers — distinct from fixed‑price centralized procurement, commonly used for competitively supplied consumables and disinfection products.
Disinfection Products Category: Managed separately from drugs and medical devices under China’s disinfection product regulations, these products (disinfectants, antiseptics, sanitizing agents for medical use) access hospital channels via provincial platforms once listed.
Automation Trend: The automatic price‑confirmation workflow streamlines what was previously manual review — part of Guangdong’s broader digitization of consumables market access with rolling monthly batches.

Market Impact & Outlook

Immediate Hospital Access: Products in this batch become procurable across Guangdong’s medical institutions right away, converting listing into commercial opportunity for successful applicants.
Price Ceiling Discipline: The “no higher than listed price” bargaining rule anchors hospital negotiations at the confirmed ceiling, reinforcing downward price pressure in the disinfection products segment.
Pipeline Watch: Enterprises whose products were held back for re‑verification or pending certificate effectiveness should expect supplementary listings in subsequent batches once conditions are met.
Rolling Cadence: The first‑batch numbering (YJHCGW39‑20260901‑XD) reflects a systematic publication schedule — suppliers not in this batch should pre‑position CA credentials, price confirmations and registration documentation ahead of the next monthly cut‑off.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the listing, deferred publication and procurement uptake of bargaining‑price disinfection products in Guangdong. Actual listing status depends on information re‑verification, registration certificate effectiveness and platform processing, and transaction volumes and prices may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100575340429578240

Guangdong Drug Exchange Center Opens Linkage Price Confirmation Window for Listed Drugs – Batch 20260917 Targets Above‑Benchmark VBP Winners and “Four‑Same” Products, With Delisting and Disqualification Risks for Non‑Compliance

Notice Snapshot

Item	Detail
Authority	Guangdong Drug Exchange Center (Guangdong Province, China)
Action	Linkage price viewing & confirmation for selected listed drugs
Batch	20260917
Product Scope	① VBP winners (incl. limited‑volume winners) whose provincial winning price exceeds other provinces’; ② same‑enterprise winners under price‑differential/comparison rules; ③ “Four‑Same” drugs listed above the national lowest listing price (as of 16 Sep 2026; details in system)
Confirmation Window	Immediate – 20 Sep 2026, 17:00
Platform	Guangdong Drug & Medical Consumables Procurement Subsystem (CA certificate login)
Policy Basis	National drug price governance requirements

Confirmation Paths & Consequences

Viewing Path (VBP winners above other provinces’ prices): Log in with CA certificate → “Drug Centralized Procurement Management – Drug Price Management – Drug Price Publication – Provincial VBP Winning Product Linkage Price Information Viewing (Batch 20260917).”
Confirmation Path (price‑differential winners & “Four‑Same” drugs): Log in with CA certificate → “Drug Price Confirmation – Provincial VBP Winning Products and ‘Four‑Same’ Drug Linkage Price Confirmation (Batch 20260917).”
Appeal Mechanism: Enterprises disputing prices must upload appeal materials stamped with the company seal on every page via the designated appeal attachment path within the window; late objections or missing evidence will in principle not be accepted.
VBP Winners Above Other Provinces: No objection, or appeal rejected → winning price adjusted downward via linkage automatically.
Price‑Differential Winners: Confirm within deadline → linkage adjustment applies; refuse confirmation with appeal rejected, or miss the deadline → winning qualification cancelled per procurement documents.
“Four‑Same” Listed Drugs: Confirm within deadline → unified price adjustment across the province’s three platforms; refuse with appeal rejected, or miss the deadline → listing revoked, with relisting only via a fresh application through the standard listing process.
Ongoing Self‑Check Duty: Enterprises must monitor prices in other provinces and submit price adjustment applications through the subsystem within 30 days of any new lower winning or listing price taking effect elsewhere.

Sector Background

Linkage Price Mechanism: Cross‑province price linkage forces listed and VBP‑winning prices toward the national lowest benchmark, a core pillar of China’s drug price governance that compresses inter‑provincial price gaps.
“Four‑Same” Targeting: Identical generic name, brand, dosage form and specification — the tightest comparability standard, closing arbitrage where the same product holds different prices across platforms.
Three‑Platform Unification: Confirmed “Four‑Same” adjustments apply uniformly across Guangdong’s three procurement platforms, eliminating within‑province price fragmentation.
Contact Channels: Online customer service via the Guangdong Drug Exchange Center website; hotlines 020‑87709875 / 020‑38036197 (weekdays 8:30–12:00, 14:00–17:30).

Market Impact & Outlook

Immediate Revenue Risk: For affected products, linkage adjustment means direct price cuts in Guangdong, one of China’s largest pharmaceutical markets — material for enterprises with concentrated provincial exposure.
Compliance Deadline Pressure: The four‑day window (closing 20 Sep, 17:00) makes timely CA‑certificate login and price confirmation operationally critical; missed deadlines trigger disqualification or delisting without further recourse.
National Price Discipline: The 30‑day self‑reporting duty institutionalizes continuous downward price surveillance — enterprises should embed cross‑province price monitoring into routine market‑access operations.
Strategic Considerations: Companies facing steep linkage cuts must weigh confirmation against withdrawal economics per product, factoring in relisting costs and the risk of setting new national price precedents.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding linkage price adjustments, appeals outcomes and potential disqualification or delisting of listed drugs in Guangdong. Actual price changes depend on enterprise confirmations, appeal adjudications and system data as of the batch cut‑off date, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100576933975691264